Abstract
Background: Enumeration and characterization of circulating tumor cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, CTCs are rare, making their isolation a major technological challenge. We developed a technique for enrichment, and subsequent characterization of CTCs based on efficient depletion of human leukocytes.
Methods: The technique (CanPatrolTM CTC enrichment) we developed is based on red blood cell lysis to remove erythrocytes, followed by depletion of CD45+ leukocytes using a magnetic bead separation method, and subsequent isolation of CTCs by virtue of their larger size, compared with leukocytes. We also demonstrated that fluorescence in situ hybridization (FISH) and genetic abnormalities analysis could be performed on the isolated CTCs.
Results: The spiking experiments showed that the average efficacy of leukocytes depletion was 99.98% and the average tumor cells recovery was not lower than 80%. FISH could be used to perform ALK gene rearrangement analysis on the collected NCI-H2228 cells, and EGFR Exon 19 deletion was detected by PCR-based analysis in isolated HCC827 cells. The in vivo feasibility of this technique had been demonstrated in patients with non-small cell lung cancer, breast, colon, and esophageal cancers. CTCs were detected in 13 of 59 blood samples. Tumor microemboli was also detected in three breast cancer samples.
Conclusions: The technique we developed allowed isolation and characterization of circulating epithelial tumor cells that do not express classical epithelial antigens. This potentially leads to a more accurate enumeration of the number of CTCs and is suitable for application to a broad range of cancers.
The authors wish to thank other members of the Research and Development department for their technical supports for this study.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006;127:679–95.10.1016/j.cell.2006.11.001Search in Google Scholar PubMed
2. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007;13:1171–8.10.1158/1078-0432.CCR-06-2329Search in Google Scholar PubMed
3. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res 2001;61:8845–50.Search in Google Scholar
4. Liu Z, Jiang M, Zhao J, Ju H. Circulating tumor cells in perioperative esophageal cancer patients: quantitative assay system and potential clinical utility. Clin Cancer Res 2007;13:2992–7.10.1158/1078-0432.CCR-06-2072Search in Google Scholar PubMed
5. Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA, Terstappen LW, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:125–32.10.3816/CCC.2006.n.029Search in Google Scholar PubMed
6. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420–30.10.1200/JCO.2005.08.140Search in Google Scholar PubMed
7. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213–21.10.1200/JCO.2007.15.8923Search in Google Scholar PubMed
8. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302–9.10.1158/1078-0432.CCR-08-0872Search in Google Scholar PubMed
9. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556–63.10.1200/JCO.2010.28.7045Search in Google Scholar PubMed
10. Yu M, Stott S, Toner M, Maheswaran S, Haber D. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192:373–82.10.1083/jcb.201010021Search in Google Scholar PubMed PubMed Central
11. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920–8.10.1158/1078-0432.CCR-06-1695Search in Google Scholar PubMed
12. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters 2007;253:180–204.10.1016/j.canlet.2006.12.014Search in Google Scholar
13. Li GQ, Luo XD, He JY, Zhu ZY, Yu G, Qin HJ, et al. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 2011;49:191–5.Search in Google Scholar
14. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366–77.10.1056/NEJMoa0800668Search in Google Scholar
15. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 1999;96:4494–9.10.1073/pnas.96.8.4494Search in Google Scholar
16. Kraus J, Pantel K, Pinkel D, Albertson DG, Speicher MR. High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer 2003;36:159–66.10.1002/gcc.10160Search in Google Scholar
17. Liu ZA, Fusi A, Klopocki E, Schmitte A, Tinhofer I, Nonnenmacher A, et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med 2011;9:70–8.10.1186/1479-5876-9-70Search in Google Scholar
18. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012;10:138–58.10.1186/1479-5876-10-138Search in Google Scholar
19. Stolpe A, Pantel K, Sleijfer S, Terstappen LW, Toonder J. Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res 2011;71:5955–60.10.1158/0008-5472.CAN-11-1254Search in Google Scholar
20. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61–6.10.1093/jnci/djn419Search in Google Scholar
21. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, et al. Isolation by size of epithelial tumor cells. Am J Pathol 2000;156:57–63.10.1016/S0002-9440(10)64706-2Search in Google Scholar
©2014 by Walter de Gruyter Berlin Boston
